The company provides B cell select mAb discovery, phage display, hybridoma development, rabbit monoclonals and antibody optimization and manufacturing.

ImmunoPrecise also has a base in The Netherlands and operates globally to offer a continuum of antibody services, promising to decrease turnaround time and risk, and promoting clinical success.